BHRC BLOG
Semaglutide Dosage Chart: Full Titration Schedule Including 7.2 mg
BHRC · WELLNESS · MEDICAL WEIGHT LOSS
Almost every semaglutide dosage chart on the internet is now out of date, because the ceiling moved. In March 2026 FDA approved a 7.2 mg dose — roughly three times the previous maintenance dose — and the rules about who it is for are specific enough that they matter. This guide lays out the complete titration schedule for every US semaglutide product, what the 7.2 mg data actually showed, the side effect FDA is still investigating, what the evidence says about muscle loss and about stopping, and where compounded versions now stand legally.
1 · The Wegovy titration schedule, in full
The schedule below is the FDA-labeled escalation. It is not a suggestion, and it is not something a good program improvises around. Each step is four weeks because that is how long the gastrointestinal side effects typically take to settle before the next increase.
Two details people miss. First, 1.7 mg is a legitimate maintenance dose, not just a waypoint — if 2.4 mg is poorly tolerated, staying at 1.7 mg is a labeled option rather than a failure. Second, escalation can be slowed. If a step is rough, a good prescriber holds you there longer rather than pushing to schedule.
2 · The 7.2 mg dose — what changed in 2026
This is the part most articles on the internet still have wrong, because it changed recently.
On 19 March 2026, FDA approved Wegovy HD, a 7.2 mg once-weekly dose, for adults with obesity or overweight with at least one weight-related condition. It was the fourth product approved under FDA’s Commissioner’s National Priority Voucher pilot, reviewed in 54 days. It became available nationwide in April 2026.
The label is specific about who it is for: patients who tolerate 2.4 mg for at least four weeks and for whom additional weight reduction is clinically indicated. There is no dose between 2.4 mg and 7.2 mg — it is a single step, roughly a threefold increase.
The thresholds are where the higher dose separates most clearly: 33.2% of patients on 7.2 mg reached at least 25% body-weight loss, against 16.7% on 2.4 mg and none on placebo. Roughly 93% of both active arms reached at least 5%.
3 · Ozempic is the same molecule on a different ladder
Semaglutide is sold under three US brand names, and conflating them is the most common source of confusion in a consultation.
The oral option is new enough to be worth spelling out. The Wegovy pill (oral semaglutide 25 mg) was approved 22 December 2025 — the first oral GLP-1 for weight management. It titrates 1.5 mg → 4 mg → 9 mg → 25 mg, thirty days per step. It has to be taken on an empty stomach in the morning with a sip of water, with nothing else — food, drink or other medication — for thirty minutes afterward. In the OASIS 4 trial it produced a mean 16.6% weight loss over 64 weeks, with about one in three reaching 20%.
4 · Side effects, and the ones that matter clinically
The common ones are gastrointestinal and dose-related, and they are the reason the ladder exists at all.
The warnings worth reading twice
- Boxed warning — thyroid C-cell tumors. Semaglutide caused these in rodents at clinically relevant exposures. Human relevance is unknown. Report a neck mass, difficulty swallowing, shortness of breath or persistent hoarseness.
- Acute pancreatitis, including fatal cases with GLP-1 medications. Severe persistent abdominal pain means stop and be evaluated.
- Gallbladder disease — cholelithiasis or cholecystitis in 1.6% on Wegovy versus 0.7% on placebo.
- Gastroparesis and ileus. Wegovy is not recommended in severe gastroparesis, and there are postmarketing reports of intestinal obstruction.
- Aspiration under anesthesia. There are rare reports in patients undergoing elective procedures despite reported fasting. Tell every surgeon, anesthesiologist and proceduralist that you are on a GLP-1 — including before aesthetic procedures with sedation.
5 · Muscle loss and what happens when you stop
These are the two questions patients actually ask, and both have real published answers.
Lean mass
In the STEP 1 body-composition substudy, total fat mass fell 19.3% while lean body mass fell 9.7% in absolute terms — but lean mass as a proportion of total body mass rose by 3.0 percentage points, and visceral fat fell 27.4%. In the SURMOUNT-1 substudy, roughly three quarters of the weight lost was fat and one quarter was lean tissue.
That ratio is broadly what happens with any substantial weight loss, including surgical. Whether the absolute lean-mass loss causes functional decline has not been tested in a trial powered to answer it. Adequate protein and resistance training are sensible and widely recommended; they have not been proven in a randomized trial to change outcomes on these drugs.
Stopping
6 · Compounded semaglutide — the window has closed
For about two years, semaglutide shortages allowed compounding pharmacies to make their own versions. That period is over, and the dates matter.
- FDA declared the semaglutide shortage resolved on 21 February 2025.
- Enforcement discretion for 503A pharmacies ended 22 April 2025; for 503B outsourcing facilities, 22 May 2025.
- On 30 April 2026, FDA proposed to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list entirely, finding no clinical need. That proposal is not yet final.
FDA’s stated concerns are worth knowing because they explain what can go wrong. Products sold as semaglutide sodium or semaglutide acetate are salt forms that are not the active ingredient in any approved drug, and FDA says it does not have information on whether they behave the same way. The agency has also documented dosing errors — patients mismeasuring, clinicians miscalculating, and products supplied with titration schedules faster than the label. As of 31 May 2026, FDA had received 990 adverse event reports for compounded semaglutide, some involving hospitalization.
7 · What a real program looks like
The difference between a medical weight-management program and a website that mails you a pen is not the molecule. It is everything around it.
1860 S Sepulveda Blvd, Los Angeles, CA 90025
(310) 861-3748 · Monday–Friday 9:00 AM – 6:00 PM, Saturday 9:00 AM – 4:00 PM
Monica Sotelo, NP · Medical direction by Dr. Stacey Naito, MD
Medical weight management is available at all six BHRC studios.
Consultations are free and carry no obligation.
Frequently Asked Questions
What is the full semaglutide dosage schedule?
For Wegovy: 0.25 mg weekly for weeks 1–4, 0.5 mg for weeks 5–8, 1 mg for weeks 9–12, 1.7 mg for weeks 13–16, then 2.4 mg from week 17 as the recommended maintenance dose. Both 1.7 mg and 2.4 mg are labeled maintenance options. For Ozempic the ladder is 0.25 → 0.5 → 1 → 2 mg, with at least four weeks at each step.
Is the 7.2 mg dose FDA-approved?
Yes. FDA approved Wegovy HD at 7.2 mg once weekly on 19 March 2026 for adults with obesity, or overweight with at least one weight-related condition. The label restricts it to patients who have tolerated 2.4 mg for at least four weeks where additional weight reduction is clinically indicated. There is no intermediate dose between 2.4 mg and 7.2 mg.
How much more weight do people lose on 7.2 mg?
In the STEP UP trial over 72 weeks, mean weight loss was 18.7% on 7.2 mg versus 15.6% on 2.4 mg and 3.9% on placebo, using the treatment-policy estimand. Among patients who were fully adherent the figures were 20.7% and 17.5%. A third of the 7.2 mg group reached at least 25% weight loss.
What is dysesthesia and should I worry about it?
It is an altered skin sensation — tingling, numbness or an odd feeling on the skin. It occurred in 22% of patients on 7.2 mg in STEP UP, versus 6% on 2.4 mg. FDA reports it generally resolved on its own or with a dose reduction, and says it is investigating the reaction further. Raise it with your prescriber before stepping up.
Can I take semaglutide as a pill?
Yes. The Wegovy pill, oral semaglutide 25 mg, was approved in December 2025 for weight management. It titrates 1.5 mg → 4 mg → 9 mg → 25 mg over 30-day steps and must be taken on an empty stomach with a sip of water, with nothing else for 30 minutes. Rybelsus is a separate oral semaglutide product for type 2 diabetes.
Will I regain the weight if I stop?
Most people regain a substantial amount. In the STEP 1 extension, participants who had lost 17.3% were at 5.6% below baseline a year after stopping — roughly two thirds of the loss regained — though 48.2% still maintained at least a 5% loss. Plan for what long-term looks like before you start.
Do I lose muscle on semaglutide?
Some lean tissue is lost alongside fat, as with any substantial weight loss. In the trial substudies roughly three quarters of weight lost was fat and one quarter lean mass, and lean mass as a proportion of body weight actually improved. Adequate protein and resistance training are sensible, though no trial has proven they change outcomes on these drugs specifically.
Is compounded semaglutide still legal?
The shortage-based allowance ended in April and May 2025 for 503A and 503B compounders respectively, and in April 2026 FDA proposed excluding semaglutide from the 503B bulks list altogether. FDA has documented nearly a thousand adverse event reports involving compounded semaglutide and warns specifically about salt forms like semaglutide sodium and acetate.
Who should not take semaglutide?
Anyone with a personal or family history of medullary thyroid carcinoma or MEN 2; anyone with a known serious hypersensitivity; anyone pregnant, planning pregnancy or breastfeeding. Severe gastroparesis is a contraindication to Wegovy specifically, and a history of pancreatitis calls for caution.
What is the first step?
A consultation with bloodwork. BHRC’s program includes thyroid testing and looks for a metabolic reason before writing a prescription — which sometimes changes the answer entirely.
Keep Reading
- Medical Weight Loss Programs at BHRC
- Tirzepatide at BHRC
- Cagrilintide + CagriSema: Titration, Trial Data & How It Works
- 5-Amino-1MQ Dosage Guide: Oral Protocol & Fat-Loss Research
- MOTS-c Peptide: How It Works, Benefits & Dosage Protocol
- Advanced Diagnostic Testing
- Longevity & Healthspan at BHRC
- Men’s Health at BHRC
Medical Weight Management at a BHRC Studio Near You
Physician-supervised weight management, with bloodwork and ongoing dose adjustment, is available at BHRC studios nationwide, including our main six. Tap your closest location to book a free consultation:
References & Further Reading
- DailyMed / U.S. National Library of Medicine — WEGOVY (semaglutide) injection and tablet — prescribing information, revised 06/2026. dailymed.nlm.nih.gov
- Novo Nordisk — WEGOVY US Prescribing Information, revised 06/2026. novo-pi.com
- Novo Nordisk — OZEMPIC US Prescribing Information, revised 05/2026. novo-pi.com
- U.S. Food & Drug Administration — FDA Approves Fourth Product Under National Priority Voucher Program, Higher Dose Semaglutide, March 2026. fda.gov
- Novo Nordisk — Semaglutide 7.2 mg achieved 20.7% weight loss in the STEP UP obesity trial — both estimands. globenewswire.com
- Novo Nordisk — FDA approves Wegovy pill, the first and only oral GLP-1 for weight loss (OASIS 4), December 2025. novonordisk.com
- Diabetes, Obesity and Metabolism — Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension, 2022. pubmed.ncbi.nlm.nih.gov
- American College of Cardiology — STEP 1: Semaglutide Treatment Effect in People With Obesity. acc.org
- U.S. Food & Drug Administration — FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. fda.gov
- U.S. Food & Drug Administration — FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. fda.gov
- U.S. Food & Drug Administration — FDA Proposes to Exclude Semaglutide, Tirzepatide and Liraglutide from the 503B Bulks List, April 2026. fda.gov
Beverly Hills Rejuvenation Center. This content is for general education and does not create a physician-patient relationship or constitute medical advice. Semaglutide is a prescription medication provided only under medical supervision after individualized evaluation. Dosing schedules shown are from FDA-approved labeling for reference and are not a prescription. Trial results are study averages, not a guarantee. Candidacy, dosing, results and pricing vary by person and are confirmed at a free consultation. Reviewed by the BHRC clinical team.
